D Saleh, K Furukawa, MS Tsao, A Maghazachi, B Corrin, M Yanagisawa, PJ Barnes and A Giaid
Department of Pathology, McGill University, Montreal, Quebec, Canada.

Endothelin-1 (ET-1) is a vasoconstrictor, bronchoconstrictor, and mitogenic peptide which is enzymatically converted from a biologically inactive big ET to mature ET (21 amino acid) by the ET-converting enzyme (ECE). Here, we investigate the expression of ECE-1, big ET-1, and ET-1 in the lungs of patients with idiopathic pulmonary fibrosis (IPF) and compare it to those of normal subjects using immunohistochemistry and in situ hybridization. In normal lungs, focal moderate expression of all three molecules is localized to airway epithelium, pulmonary endothelium, and airway and vascular smooth muscle cells. Serous bronchial glands also expressed ET-1 and ECE-1. In IPF, strong diffuse expression of ECE-1 was seen in airway epithelium, proliferating type II pneumocytes, and in endothelial and inflammatory cells. ECE-1 immunostaining was colocalized to big ET-1 and ET-1 immunostaining, and correlated with disease activity (P < 0.05). To study regulatory mechanisms of ET-1 and ECE-1 expression, human normal bronchial epithelial (NBE) cells were treated with cytokines and analyzed by radioimmunoassay and Northern blot. Incubation of human NBE cells with IL-1alpha and -beta or tumor necrosis factor alpha (TNFalpha) resulted in a significant increase in ET-1 release and mRNA expression. TNFalpha resulted in a significant increase in ECE-1 mRNA expression. These findings demonstrated the colocalization of the precursor and active ET-1, and ECE-1 in the same cell, and that ECE-1 expression is elevated in IPF. In addition, increased expression of ET- 1 and ECE-1 in IPF may be mediated by proinflammatory cytokines.

This article has been cited by other articles:

				D. Abraham Role of endothelin in lung fibrosis Eur. Respir. Rev., December 1, 2008; 17(109): 145 - 150. [Abstract] [Full Text] [PDF]

				P. Rogliani, M. Mura, M. Assunta Porretta, and C. Saltini Review: New perspectives in the treatment of idiopathic pulmonary fibrosis Therapeutic Advances in Respiratory Disease, April 1, 2008; 2(2): 75 - 93. [Abstract] [PDF]

				R. Jain, P. W. Shaul, Z. Borok, and B. C. Willis Endothelin-1 Induces Alveolar Epithelial-Mesenchymal Transition through Endothelin Type A Receptor-Mediated Production of TGF-beta1 Am. J. Respir. Cell Mol. Biol., July 1, 2007; 37(1): 38 - 47. [Abstract] [Full Text] [PDF]

				S. D. Nathan, P. W. Noble, and R. M. Tuder Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension: Connecting the Dots Am. J. Respir. Crit. Care Med., May 1, 2007; 175(9): 875 - 880. [Abstract] [Full Text] [PDF]

				A. Gunther, B. Enke, P. Markart, P. Hammerl, H. Morr, J. Behr, G. Stahler, W. Seeger, F. Grimminger, I. Leconte, et al. Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study Eur. Respir. J., April 1, 2007; 29(4): 713 - 719. [Abstract] [Full Text] [PDF]

				B. S. Zuckerbraun, B. Y. Chin, B. Wegiel, T. R. Billiar, E. Czsimadia, J. Rao, L. Shimoda, E. Ifedigbo, S. Kanno, and L. E. Otterbein Carbon monoxide reverses established pulmonary hypertension J. Exp. Med., September 4, 2006; 203(9): 2109 - 2119. [Abstract] [Full Text] [PDF]

				B. Houweling, D. Merkus, O. Sorop, F. Boomsma, and D. J. Duncker Role of endothelin receptor activation in secondary pulmonary hypertension in awake swine after myocardial infarction J. Physiol., July 15, 2006; 574(2): 615 - 626. [Abstract] [Full Text] [PDF]

				D. Bouros and K. M. Antoniou Current and future therapeutic approaches in idiopathic pulmonary fibrosis Eur. Respir. J., October 1, 2005; 26(4): 693 - 703. [Abstract] [Full Text] [PDF]

				M. P.B. Wijayagunawardane, C. Gabler, G. Killian, and A. Miyamoto Tumor Necrosis Factor {alpha} in the Bovine Oviduct During the Estrous Cycle: Messenger RNA Expression and Effect on Secretion of Prostaglandins, Endothelin-1, and Angiotensin II Biol Reprod, October 1, 2003; 69(4): 1341 - 1346. [Abstract] [Full Text] [PDF]

				P. Teder and P. W. Noble A Cytokine Reborn? . Endothelin-1 in Pulmonary Inflammation and Fibrosis Am. J. Respir. Cell Mol. Biol., July 1, 2000; 23(1): 7 - 10. [Full Text]

				B. Hocher, A. Schwarz, K. A. Fagan, C. Thöne-Reineke, K. El-Hag, H. Kusserow, S. Elitok, C. Bauer, H.-H. Neumayer, D. M. Rodman, et al. Pulmonary Fibrosis and Chronic Lung Inflammation in ET-1 Transgenic Mice Am. J. Respir. Cell Mol. Biol., July 1, 2000; 23(1): 19 - 26. [Abstract] [Full Text]

				R. J. MASON, M. I. SCHWARZ, G. W. HUNNINGHAKE, and R. A. MUSSON Pharmacological Therapy for Idiopathic Pulmonary Fibrosis . Past, Present, and Future Am. J. Respir. Crit. Care Med., November 1, 1999; 160(5): 1771 - 1777. [Full Text]

				K. Ono, A. Matsumori, T. Shioi, Y. Furukawa, and S. Sasayama Contribution of Endothelin-1 to Myocardial Injury in a Murine Model of Myocarditis : Acute Effects of Bosentan, an Endothelin Receptor Antagonist Circulation, October 26, 1999; 100(17): 1823 - 1829. [Abstract] [Full Text] [PDF]

				H. F. Frasch, C. Marshall, and B. E. Marshall Endothelin-1 is elevated in monocrotaline pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, February 1, 1999; 276(2): L304 - L310. [Abstract] [Full Text] [PDF]

				R. Shao, W. Yan, and D. C. Rockey Regulation of Endothelin-1 Synthesis by Endothelin-converting Enzyme-1 during Wound Healing J. Biol. Chem., January 29, 1999; 274(5): 3228 - 3234. [Abstract] [Full Text] [PDF]

				S.-H. PARK, D. SALEH, A. GIAID, and R. P. MICHEL Increased Endothelin-1 in Bleomycin-induced Pulmonary Fibrosis and the Effect of an Endothelin Receptor Antagonist Am. J. Respir. Crit. Care Med., July 1, 1997; 156(2): 600 - 608. [Abstract] [Full Text]